Biocon Limited

“Biocon generates 6% ROCE on ₹18,000 Cr of acquisition debt, with promoters liquidating a 16-percentage-point stake while the business earns 5% ROE. The biosimilar market provides a long runway but structurally weak pricing power caps margins well below cost of capital. At 72x trailing earnings, the stock prices in a transformation the company has never demonstrated across two decades of operations. Probability-weighted intrinsic value of ₹275 at 5 years implies capital destruction from ₹353. Every dimension — business quality, moat, financials, governance, valuation — signals avoid. There is no margin of safety and no catalyst for re-rating absent a fundamental restructuring of returns on capital that management has shown no ability to execute.”